<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39351195</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-0042</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>iScience</Title><ISOAbbreviation>iScience</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity.</ArticleTitle><Pagination><StartPage>110624</StartPage><MedlinePgn>110624</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">110624</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.isci.2024.110624</ELocationID><Abstract><AbstractText>The rapid emergence of SARS-CoV-2 variants of concern (VoC) and the threat of future zoonotic sarbecovirus spillover emphasizes the need for broadly protective next-generation vaccines and therapeutics. We utilized SARS-CoV-2 spike ferritin nanoparticle (SpFN), and SARS-CoV-2 receptor binding domain ferritin nanoparticle (RFN) immunogens, in an equine model to elicit hyperimmune sera and evaluated its sarbecovirus neutralization and protection capacity. Immunized animals rapidly elicited sera with the potent neutralization of SARS-CoV-2 VoC, and SARS-CoV-1 pseudoviruses, and potent binding against receptor binding domains from sarbecovirus clades 1b, 1a, 2, 3, and 4. Purified equine polyclonal IgG provided protection against Omicron XBB.1.5 virus in the K18-hACE2 transgenic mouse model. These results suggest that SARS-CoV-2-based nanoparticle vaccines can rapidly produce a broad and protective sarbecovirus response in the equine model and that equine serum has therapeutic potential against emerging SARS-CoV-2 VoC and diverse sarbecoviruses, presenting a possible alternative or supplement to monoclonal antibody immunotherapies.</AbstractText><CopyrightInformation>© 2024 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Elizabeth J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>William C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei-Hung</ForeName><Initials>WH</Initials><AffiliationInfo><Affiliation>Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hajduczki</LastName><ForeName>Agnes</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Paul V</ForeName><Initials>PV</Initials><AffiliationInfo><Affiliation>Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Jaime L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choe</LastName><ForeName>Misook</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sankhala</LastName><ForeName>Rajeshwer S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Caroline E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rees</LastName><ForeName>Phyllis A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimner</LastName><ForeName>Jordan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soman</LastName><ForeName>Sandrine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuklis</LastName><ForeName>Caitlin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendez-Rivera</LastName><ForeName>Letzibeth</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dussupt</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Jocelyn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corbett</LastName><ForeName>Courtney</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Sandra V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandes</LastName><ForeName>Aldon</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bharat Serums and Vaccines Ltd., Mumbai, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murzello</LastName><ForeName>Kripa</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cookenham</LastName><ForeName>Tres</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hvizdos</LastName><ForeName>Janine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kummer</LastName><ForeName>Larry</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hart</LastName><ForeName>Tricia</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanzer</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gambacurta</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reagan</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duso</LastName><ForeName>Debbie</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasan</LastName><ForeName>Sandhya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Natalie D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michael</LastName><ForeName>Nelson L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krebs</LastName><ForeName>Shelly J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gromowski</LastName><ForeName>Gregory D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Modjarrad</LastName><ForeName>Kayvon</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaundinya</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>BSV Biosciences, Inc., Morgan Hill, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joyce</LastName><ForeName>M Gordon</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>iScience</MedlineTA><NlmUniqueID>101724038</NlmUniqueID><ISSNLinking>2589-0042</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Immunology</Keyword><Keyword MajorTopicYN="N">Virology</Keyword></KeywordList><CoiStatement>W.H.C, A.H., P.V.T., J.L.J., K.M. and M.G.J. are named inventors on provisional patents describing SpFN molecules. S.J.K., V.D., N.L.M., and K.M. are named inventors on provisional patents describing monoclonal antibodies against coronaviruses. M.G.J. is named as an inventor on international patent application WO/2018/081318 and U.S. patents 10,960,070, and 11,964,010 entitled “Prefusion coronavirus spike proteins and their use.” K.M. is a current employee of Pfizer and may, therefore, be a shareholder. A.F., K.Mur., and J.Kau. are former or current employees of B.S.V. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>4</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39351195</ArticleId><ArticleId IdType="pmc">PMC11440237</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2024.110624</ArticleId><ArticleId IdType="pii">S2589-0042(24)01849-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Starr T.N., Zepeda S.K., Walls A.C., Greaney A.J., Alkhovsky S., Veesler D., Bloom J.D. ACE2 binding is an ancestral and evolvable trait of sarbecoviruses. Nature. 2022;603:913–918. doi: 10.1038/s41586-022-04464-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04464-z</ArticleId><ArticleId IdType="pmc">PMC8967715</ArticleId><ArticleId IdType="pubmed">35114688</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells H.L., Letko M., Lasso G., Ssebide B., Nziza J., Byarugaba D.K., Navarrete-Macias I., Liang E., Cranfield M., Han B.A., et al. The evolutionary history of ACE2 usage within the coronavirus subgenus Sarbecovirus. Virus Evol. 2021;7 doi: 10.1093/ve/veab007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ve/veab007</ArticleId><ArticleId IdType="pmc">PMC7928622</ArticleId><ArticleId IdType="pubmed">33754082</ArticleId></ArticleIdList></Reference><Reference><Citation>Boni M.F., Lemey P., Jiang X., Lam T.T.Y., Perry B.W., Castoe T.A., Rambaut A., Robertson D.L. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. Nat. Microbiol. 2020;5:1408–1417. doi: 10.1038/s41564-020-0771-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0771-4</ArticleId><ArticleId IdType="pubmed">32724171</ArticleId></ArticleIdList></Reference><Reference><Citation>Heffron A.S., McIlwain S.J., Amjadi M.F., Baker D.A., Khullar S., Armbrust T., Halfmann P.J., Kawaoka Y., Sethi A.K., Palmenberg A.C., et al. The landscape of antibody binding in SARS-CoV-2 infection. PLoS Biol. 2021;19 doi: 10.1371/journal.pbio.3001265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3001265</ArticleId><ArticleId IdType="pmc">PMC8245122</ArticleId><ArticleId IdType="pubmed">34143766</ArticleId></ArticleIdList></Reference><Reference><Citation>Racine T., Denizot M., Pannetier D., Nguyen L., Pasquier A., Raoul H., Saluzzo J.F., Kobinger G., Veas F., Herbreteau C.H. In Vitro Characterization and In Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab')2. J. Infect. Dis. 2019;220:41–45. doi: 10.1093/infdis/jiz068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiz068</ArticleId><ArticleId IdType="pubmed">30852585</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreano E., Piccini G., Licastro D., Casalino L., Johnson N.V., Paciello I., Dal Monego S., Pantano E., Manganaro N., Manenti A., et al. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. Proc. Natl. Acad. Sci. USA. 2021;118 doi: 10.1073/pnas.2103154118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2103154118</ArticleId><ArticleId IdType="pmc">PMC8433494</ArticleId><ArticleId IdType="pubmed">34417349</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R.E., Zhang X., Case J.B., Winkler E.S., Liu Y., VanBlargan L.A., Liu J., Errico J.M., Xie X., Suryadevara N., et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 2021;27:717–726. doi: 10.1038/s41591-021-01294-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01294-w</ArticleId><ArticleId IdType="pmc">PMC8058618</ArticleId><ArticleId IdType="pubmed">33664494</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier D.A., De Marco A., Ferreira I.A.T.M., Meng B., Datir R.P., Walls A.C., Kemp S.A., Bassi J., Pinto D., Silacci-Fregni C., et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021;593:136–141. doi: 10.1038/s41586-021-03412-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03412-7</ArticleId><ArticleId IdType="pubmed">33706364</ArticleId></ArticleIdList></Reference><Reference><Citation>Dussupt V., Sankhala R.S., Mendez-Rivera L., Townsley S.M., Schmidt F., Wieczorek L., Lal K.G., Donofrio G.C., Tran U., Jackson N.D., et al. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. Nat. Immunol. 2021;22:1503–1514. doi: 10.1038/s41590-021-01068-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01068-z</ArticleId><ArticleId IdType="pmc">PMC8642242</ArticleId><ArticleId IdType="pubmed">34716452</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurini E., Marson D., Aulic S., Fermeglia A., Pricl S. Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies. Sci. Rep. 2021;11 doi: 10.1038/s41598-021-99827-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-99827-3</ArticleId><ArticleId IdType="pmc">PMC8511038</ArticleId><ArticleId IdType="pubmed">34642465</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Guo Y., Iketani S., Nair M.S., Li Z., Mohri H., Wang M., Yu J., Bowen A.D., Chang J.Y., et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, &amp; BA.5. Nature. 2022;608:603–608. doi: 10.1038/s41586-022-05053-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05053-w</ArticleId><ArticleId IdType="pmc">PMC9385487</ArticleId><ArticleId IdType="pubmed">35790190</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Zhang Q., Zhang R., Aw Z.Q., Chen P., Wong Y.H., Hong J., Ju B., Shi X., Ding Q., et al. SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2. Front. Immunol. 2022;13 doi: 10.3389/fimmu.2022.854952.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.854952</ArticleId><ArticleId IdType="pmc">PMC9247160</ArticleId><ArticleId IdType="pubmed">35784344</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuekprakhon A., Nutalai R., Dijokaite-Guraliuc A., Zhou D., Ginn H.M., Selvaraj M., Liu C., Mentzer A.J., Supasa P., Duyvesteyn H.M.E., et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185:2422–2433.e13. doi: 10.1016/j.cell.2022.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.06.005</ArticleId><ArticleId IdType="pmc">PMC9181312</ArticleId><ArticleId IdType="pubmed">35772405</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Yisimayi A., Jian F., Song W., Xiao T., Wang L., Du S., Wang J., Li Q., Chen X., et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608:593–602. doi: 10.1038/s41586-022-04980-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04980-y</ArticleId><ArticleId IdType="pmc">PMC9385493</ArticleId><ArticleId IdType="pubmed">35714668</ArticleId></ArticleIdList></Reference><Reference><Citation>Iketani S., Liu L., Guo Y., Liu L., Chan J.F.W., Huang Y., Wang M., Luo Y., Yu J., Chu H., et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022;604:553–556. doi: 10.1038/s41586-022-04594-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04594-4</ArticleId><ArticleId IdType="pmc">PMC9021018</ArticleId><ArticleId IdType="pubmed">35240676</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Iketani S., Guo Y., Chan J.F.W., Wang M., Liu L., Luo Y., Chu H., Huang Y., Nair M.S., et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022;602:676–681. doi: 10.1038/s41586-021-04388-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04388-0</ArticleId><ArticleId IdType="pubmed">35016198</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannar D., Saville J.W., Zhu X., Srivastava S.S., Berezuk A.M., Tuttle K.S., Marquez A.C., Sekirov I., Subramaniam S. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex. Science. 2022;375:760–764. doi: 10.1126/science.abn7760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn7760</ArticleId><ArticleId IdType="pmc">PMC9799367</ArticleId><ArticleId IdType="pubmed">35050643</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallum M., Czudnochowski N., Rosen L.E., Zepeda S.K., Bowen J.E., Walls A.C., Hauser K., Joshi A., Stewart C., Dillen J.R., et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science. 2022;375:864–868. doi: 10.1126/science.abn8652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn8652</ArticleId><ArticleId IdType="pmc">PMC9427005</ArticleId><ArticleId IdType="pubmed">35076256</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabel K.G., Clark S.A., Shankar S., Pan J., Clark L.E., Yang P., Coscia A., McKay L.G.A., Varnum H.H., Brusic V., et al. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. Science. 2022;375 doi: 10.1126/science.abl6251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abl6251</ArticleId><ArticleId IdType="pmc">PMC9127715</ArticleId><ArticleId IdType="pubmed">34855508</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P., Nair M.S., Liu L., Iketani S., Luo Y., Guo Y., Wang M., Yu J., Zhang B., Kwong P.D., et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593:130–135. doi: 10.1038/s41586-021-03398-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03398-2</ArticleId><ArticleId IdType="pubmed">33684923</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Bruel T., Staropoli I., Guivel-Benhassine F., Porrot F., Maes P., Grzelak L., Prot M., Mougari S., Planchais C., et al. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. Nat. Commun. 2023;14:824. doi: 10.1038/s41467-023-36561-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-36561-6</ArticleId><ArticleId IdType="pmc">PMC9926440</ArticleId><ArticleId IdType="pubmed">36788246</ArticleId></ArticleIdList></Reference><Reference><Citation>Lusvarghi S., Pollett S.D., Neerukonda S.N., Wang W., Wang R., Vassell R., Epsi N.J., Fries A.C., Agan B.K., Lindholm D.A., et al. SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies. Sci. Transl. Med. 2022;14 doi: 10.1126/scitranslmed.abn8543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abn8543</ArticleId><ArticleId IdType="pmc">PMC8995032</ArticleId><ArticleId IdType="pubmed">35380448</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurhade C., Zou J., Xia H., Liu M., Yang Q., Cutler M., Cooper D., Muik A., Sahin U., Jansen K.U., et al. Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by 3 doses of BNT162b2 vaccine or BA.1 infection. Emerg. Microb. Infect. 2022;11:1828–1832. doi: 10.1080/22221751.2022.2099305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2099305</ArticleId><ArticleId IdType="pmc">PMC9331225</ArticleId><ArticleId IdType="pubmed">35792746</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekliz M., Adea K., Vetter P., Eberhardt C.S., Hosszu-Fellous K., Vu D.L., Puhach O., Essaidi-Laziosi M., Waldvogel-Abramowski S., Stephan C., et al. Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs. Nat. Commun. 2022;13:3840. doi: 10.1038/s41467-022-31556-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31556-1</ArticleId><ArticleId IdType="pmc">PMC9253337</ArticleId><ArticleId IdType="pubmed">35787633</ArticleId></ArticleIdList></Reference><Reference><Citation>Self W.H., Wheeler A.P., Stewart T.G., Schrager H., Mallada J., Thomas C.B., Cataldo V.D., O'Neal H.R., Jr., Shapiro N.I., Higgins C., et al. Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19: A Blinded, Randomized, Placebo-Controlled Trial. Chest. 2022;162:982–994. doi: 10.1016/j.chest.2022.06.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2022.06.029</ArticleId><ArticleId IdType="pmc">PMC9247217</ArticleId><ArticleId IdType="pubmed">35780813</ArticleId></ArticleIdList></Reference><Reference><Citation>Casadevall A., Joyner M.J., Pirofski L.A., Senefeld J.W., Shoham S., Sullivan D., Paneth N., Focosi D. Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy. Expet Rev. Respir. Med. 2023;17:381–395. doi: 10.1080/17476348.2023.2208349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17476348.2023.2208349</ArticleId><ArticleId IdType="pubmed">37129285</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner M.J., Paneth N., Casadevall A. Use of convalescent plasma in the treatment of COVID-19. Nat. Rev. Nephrol. 2023;19:271. doi: 10.1038/s41581-023-00690-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-023-00690-4</ArticleId><ArticleId IdType="pmc">PMC9937736</ArticleId><ArticleId IdType="pubmed">36806372</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchini M., Casadevall A., Joyner M.J., Focosi D. WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients? Life. 2023;13 doi: 10.3390/life13010134.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life13010134</ArticleId><ArticleId IdType="pmc">PMC9867306</ArticleId><ArticleId IdType="pubmed">36676084</ArticleId></ArticleIdList></Reference><Reference><Citation>Senefeld J.W., Paneth N.S., Carter R.E., Wright R.S., Fairweather D., Bruno K.A., Joyner M.J. Late Treatment for COVID-19 With Convalescent Plasma. Chest. 2022;162:e283–e284. doi: 10.1016/j.chest.2022.07.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2022.07.029</ArticleId><ArticleId IdType="pmc">PMC9634046</ArticleId><ArticleId IdType="pubmed">36344142</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutiérrez J.M., Lomonte B., Sanz L., Calvete J.J., Pla D. Immunological profile of antivenoms: preclinical analysis of the efficacy of a polyspecific antivenom through antivenomics and neutralization assays. J. Proteonomics. 2014;105:340–350. doi: 10.1016/j.jprot.2014.02.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jprot.2014.02.021</ArticleId><ArticleId IdType="pubmed">24583507</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira-Soto A., Arguedas M., Brenes H., Buján W., Corrales-Aguilar E., Díaz C., Echeverri A., Flores-Díaz M., Gómez A., Hernández A., et al. High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern. Front. Med. 2021;8 doi: 10.3389/fmed.2021.735853.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.735853</ArticleId><ArticleId IdType="pmc">PMC8451950</ArticleId><ArticleId IdType="pubmed">34552949</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponchner D. Scientific American; 2020. Antibodies for Trials as an Inexpensive COVID-19 Therapy.</Citation></Reference><Reference><Citation>da Costa C.B.P., Martins F.J., da Cunha L.E.R., Ratcliffe N.A., Cisne de Paula R., Castro H.C. COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus. Int. Immunopharm. 2021;90 doi: 10.1016/j.intimp.2020.107220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.107220</ArticleId><ArticleId IdType="pmc">PMC7678452</ArticleId><ArticleId IdType="pubmed">33302034</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledsgaard L., Jenkins T.P., Davidsen K., Krause K.E., Martos-Esteban A., Engmark M., Rørdam Andersen M., Lund O., Laustsen A.H. Antibody Cross-Reactivity in Antivenom Research. Toxins. 2018;10 doi: 10.3390/toxins10100393.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/toxins10100393</ArticleId><ArticleId IdType="pmc">PMC6215175</ArticleId><ArticleId IdType="pubmed">30261694</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit R., Herz J., Dalton R., Booy R. Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens. Vaccine. 2016;34:1152–1161. doi: 10.1016/j.vaccine.2016.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.01.016</ArticleId><ArticleId IdType="pmc">PMC7131169</ArticleId><ArticleId IdType="pubmed">26802604</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan X., Wu Y., Wang W., Zhang L., Xiao G. Development of horse neutralizing immunoglobulin and immunoglobulin fragments against Junin virus. Antivir. Res. 2020;174 doi: 10.1016/j.antiviral.2019.104666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2019.104666</ArticleId><ArticleId IdType="pmc">PMC7114285</ArticleId><ArticleId IdType="pubmed">31760108</ArticleId></ArticleIdList></Reference><Reference><Citation>Bermúdez-Méndez E., Fuglsang-Madsen A., Føns S., Lomonte B., Gutiérrez J.M., Laustsen A.H. Innovative Immunization Strategies for Antivenom Development. Toxins. 2018;10:452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6265855</ArticleId><ArticleId IdType="pubmed">30400220</ArticleId></ArticleIdList></Reference><Reference><Citation>Waghmare A., Deopurkar R.L., Salvi N., Khadilkar M., Kalolikar M., Gade S.K. Comparison of Montanide adjuvants, IMS 3012 (Nanoparticle), ISA 206 and ISA 35 (Emulsion based) along with incomplete Freund's adjuvant for hyperimmunization of equines used for production of polyvalent snake antivenom. Vaccine. 2009;27:1067–1072. doi: 10.1016/j.vaccine.2008.11.103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.11.103</ArticleId><ArticleId IdType="pubmed">19100805</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X., Wong G., Zhao Y., Wang H., He S., Bi Y., Chen W., Jin H., Gai W., Chu D., et al. Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection. Sci. Rep. 2016;6 doi: 10.1038/srep24179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep24179</ArticleId><ArticleId IdType="pmc">PMC4828711</ArticleId><ArticleId IdType="pubmed">27067649</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Wang C., Qiu B., Li C., Wang H., Jin H., Gai W., Zheng X., Wang T., Sun W., et al. Passive immunotherapy for Middle East Respiratory Syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model. Antivir. Res. 2017;137:125–130. doi: 10.1016/j.antiviral.2016.11.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.11.016</ArticleId><ArticleId IdType="pmc">PMC7113855</ArticleId><ArticleId IdType="pubmed">27890674</ArticleId></ArticleIdList></Reference><Reference><Citation>Farizano Salazar D.H., Achinelli F., Colonna M., Pérez L., Giménez A.A., Ojeda M.A., Miranda Puente S.N., Sánchez Negrette L., Cañete F., Martelotte Ibarra O.I., et al. Safety and effectiveness of RBD-specific polyclonal equine F(ab )2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study. PLoS One. 2022;17 doi: 10.1371/journal.pone.0274796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0274796</ArticleId><ArticleId IdType="pmc">PMC9512184</ArticleId><ArticleId IdType="pubmed">36155545</ArticleId></ArticleIdList></Reference><Reference><Citation>Li E., Han Q., Bi J., Wei S., Wang S., Zhang Y., Liu J., Feng N., Wang T., Wu J., et al. Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection. Front. Immunol. 2023;14 doi: 10.3389/fimmu.2023.1066730.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1066730</ArticleId><ArticleId IdType="pmc">PMC9981790</ArticleId><ArticleId IdType="pubmed">36875106</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Nuñez M., Cepeda M.D.V., Bello C., Lopez M.A., Sulbaran Y., Loureiro C.L., Liprandi F., Jaspe R.C., Pujol F.H., Rangel H.R. Neutralization of Different Variants of SARS-CoV-2 by a F(ab')2 Preparation from Sera of Horses Immunized with the Viral Receptor Binding Domain. Antibodies. 2023;12 doi: 10.3390/antib12040080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib12040080</ArticleId><ArticleId IdType="pmc">PMC10740526</ArticleId><ArticleId IdType="pubmed">38131802</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Wu H., Egland K.A., Gilliland T.C., Dunn M.D., Luke T.C., Sullivan E.J., Klimstra W.B., Bausch C.L., Whelan S.P.J. Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants. Hum. Vaccines Immunother. 2022;18 doi: 10.1080/21645515.2021.1940652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2021.1940652</ArticleId><ArticleId IdType="pmc">PMC8290372</ArticleId><ArticleId IdType="pubmed">34228597</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang J., Grubbs G., Lee Y., Wu H., Luke T.C., Egland K.A., Bausch C.L., Sullivan E.J., Khurana S. Increased Antibody Avidity and Cross-Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Variants by Hyperimmunized Transchromosomic Bovine-Derived Human Immunoglobulins for Treatment of Coronavirus Disease 2019. J. Infect. Dis. 2022;226:655–663. doi: 10.1093/infdis/jiac031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac031</ArticleId><ArticleId IdType="pmc">PMC8903330</ArticleId><ArticleId IdType="pubmed">35106573</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilliland T., Dunn M., Liu Y., Alcorn M.D.H., Terada Y., Vasilatos S., Lundy J., Li R., Nambulli S., Larson D., et al. Transchromosomic bovine-derived anti-SARS-CoV-2 polyclonal human antibodies protects hACE2 transgenic hamsters against multiple variants. iScience. 2023;26 doi: 10.1016/j.isci.2023.107764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2023.107764</ArticleId><ArticleId IdType="pmc">PMC10509298</ArticleId><ArticleId IdType="pubmed">37736038</ArticleId></ArticleIdList></Reference><Reference><Citation>Taiwo B.O., Chew K.W., Moser C., Wohl D.A., Daar E.S., Li J.Z., Greninger A.L., Bausch C., Luke T., Hoover K., et al. Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19. J. Infect. Dis. 2023;228:133–142. doi: 10.1093/infdis/jiad013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad013</ArticleId><ArticleId IdType="pmc">PMC10345463</ArticleId><ArticleId IdType="pubmed">36661240</ArticleId></ArticleIdList></Reference><Reference><Citation>Saied A.A., Nascimento M.S.L., do Nascimento Rangel A.H., Skowron K., Grudlewska-Buda K., Dhama K., Shah J., Abdeen A., El-Mayet F.S., Ahmed H., Metwally A.A. Transchromosomic bovines-derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS-CoV-2, MERS-CoV, Ebola, Zika, HIV-1, and influenza A virus. J. Med. Virol. 2022;94:4599–4610. doi: 10.1002/jmv.27907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27907</ArticleId><ArticleId IdType="pmc">PMC9347534</ArticleId><ArticleId IdType="pubmed">35655326</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce M.G., Chen W.H., Sankhala R.S., Hajduczki A., Thomas P.V., Choe M., Martinez E.J., Chang W.C., Peterson C.E., Morrison E.B., et al. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell Rep. 2021;37 doi: 10.1016/j.celrep.2021.110143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.110143</ArticleId><ArticleId IdType="pmc">PMC8651551</ArticleId><ArticleId IdType="pubmed">34919799</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce M.G., King H.A.D., Elakhal-Naouar I., Ahmed A., Peachman K.K., Macedo Cincotta C., Subra C., Chen R.E., Thomas P.V., Chen W.H., et al. A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. Sci. Transl. Med. 2022;14 doi: 10.1126/scitranslmed.abi5735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abi5735</ArticleId><ArticleId IdType="pubmed">34914540</ArticleId></ArticleIdList></Reference><Reference><Citation>King H.A.D., Joyce M.G., Lakhal-Naouar I., Ahmed A., Cincotta C.M., Subra C., Peachman K.K., Hack H.R., Chen R.E., Thomas P.V., et al. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. Proc. Natl. Acad. Sci. USA. 2021;118 doi: 10.1073/pnas.2106433118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2106433118</ArticleId><ArticleId IdType="pmc">PMC8463842</ArticleId><ArticleId IdType="pubmed">34470866</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuertz K.M., Barkei E.K., Chen W.H., Martinez E.J., Lakhal-Naouar I., Jagodzinski L.L., Paquin-Proulx D., Gromowski G.D., Swafford I., Ganesh A., et al. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. NPJ Vaccines. 2021;6:129. doi: 10.1038/s41541-021-00392-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-021-00392-7</ArticleId><ArticleId IdType="pmc">PMC8553838</ArticleId><ArticleId IdType="pubmed">34711815</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrivastava S., Carmen J.M., Lu Z., Basu S., Sankhala R.S., Chen W.H., Nguyen P., Chang W.C., King J., Corbitt C., et al. SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies. NPJ Vaccines. 2023;8:43. doi: 10.1038/s41541-023-00638-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00638-6</ArticleId><ArticleId IdType="pmc">PMC10024299</ArticleId><ArticleId IdType="pubmed">36934088</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston S.C., Ricks K.M., Lakhal-Naouar I., Jay A., Subra C., Raymond J.L., King H.A.D., Rossi F., Clements T.L., Fetterer D., et al. A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model. Vaccines. 2022;10 doi: 10.3390/vaccines10050717.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050717</ArticleId><ArticleId IdType="pmc">PMC9145473</ArticleId><ArticleId IdType="pubmed">35632473</ArticleId></ArticleIdList></Reference><Reference><Citation>Ober Shepherd B.L., Scott P.T., Hutter J.N., Lee C., McCauley M.D., Guzman I., Bryant C., McGuire S., Kennedy J., Chen W.H., et al. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial. Lancet. Microbe. 2024;5:e581–e593. doi: 10.1016/S2666-5247(23)00410-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(23)00410-X</ArticleId><ArticleId IdType="pmc">PMC11192176</ArticleId><ArticleId IdType="pubmed">38761816</ArticleId></ArticleIdList></Reference><Reference><Citation>Dussupt V., Sankhala R.S., Gromowski G.D., Donofrio G., De La Barrera R.A., Larocca R.A., Zaky W., Mendez-Rivera L., Choe M., Davidson E., et al. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. Nat. Med. 2020;26:228–235. doi: 10.1038/s41591-019-0746-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0746-2</ArticleId><ArticleId IdType="pmc">PMC7018608</ArticleId><ArticleId IdType="pubmed">32015557</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheaffer S.M., Lee D., Whitener B., Ying B., Wu K., Liang C.Y., Jani H., Martin P., Amato N.J., Avena L.E., et al. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. Nat. Med. 2023;29:247–257. doi: 10.1038/s41591-022-02092-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02092-8</ArticleId><ArticleId IdType="pubmed">36265510</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis-Gardner M.E., Lai L., Wali B., Samaha H., Solis D., Lee M., Porter-Morrison A., Hentenaar I.T., Yamamoto F., Godbole S., et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. N. Engl. J. Med. 2023;388:183–185. doi: 10.1056/NEJMc2214293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2214293</ArticleId><ArticleId IdType="pmc">PMC9812288</ArticleId><ArticleId IdType="pubmed">36546661</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurhade C., Zou J., Xia H., Liu M., Chang H.C., Ren P., Xie X., Shi P.Y. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster. Nat. Med. 2023;29:344–347. doi: 10.1038/s41591-022-02162-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02162-x</ArticleId><ArticleId IdType="pubmed">36473500</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Iketani S., Li Z., Liu L., Guo Y., Huang Y., Bowen A.D., Liu M., Wang M., Yu J., et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186:279–286.e8. doi: 10.1016/j.cell.2022.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.12.018</ArticleId><ArticleId IdType="pmc">PMC9747694</ArticleId><ArticleId IdType="pubmed">36580913</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnus C.L., Hiergeist A., Schuster P., Rohrhofer A., Medenbach J., Gessner A., Peterhoff D., Schmidt B. Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab. Front. Immunol. 2022;13 doi: 10.3389/fimmu.2022.966236.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.966236</ArticleId><ArticleId IdType="pmc">PMC9449809</ArticleId><ArticleId IdType="pubmed">36090991</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D., Quiroga R., McConnell S., Johnson M.C., Casadevall A. Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge. Int. J. Mol. Sci. 2023;24 doi: 10.3390/ijms24032264.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24032264</ArticleId><ArticleId IdType="pmc">PMC9917121</ArticleId><ArticleId IdType="pubmed">36768588</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox M., Peacock T.P., Harvey W.T., Hughes J., Wright D.W., COVID-19 Genomics UK COG-UK Consortium. Willett B.J., Thomson E., Gupta R.K., Peacock S.J., et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat. Rev. Microbiol. 2023;21:112–124. doi: 10.1038/s41579-022-00809-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00809-7</ArticleId><ArticleId IdType="pmc">PMC9616429</ArticleId><ArticleId IdType="pubmed">36307535</ArticleId></ArticleIdList></Reference><Reference><Citation>Rappazzo C.G., Tse L.V., Kaku C.I., Wrapp D., Sakharkar M., Huang D., Deveau L.M., Yockachonis T.J., Herbert A.S., Battles M.B., et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. 2021;371:823–829. doi: 10.1126/science.abf4830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf4830</ArticleId><ArticleId IdType="pmc">PMC7963221</ArticleId><ArticleId IdType="pubmed">33495307</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J., Thomas P.V., McMahan K., Jacob-Dolan C., Liu J., He X., Hope D., Martinez E.J., Chen W.H., Sciacca M., et al. Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN. Sci. Adv. 2022;8 doi: 10.1126/sciadv.ade4433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.ade4433</ArticleId><ArticleId IdType="pmc">PMC9683731</ArticleId><ArticleId IdType="pubmed">36417525</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankhala R.S., Lal K.G., Jensen J.L., Dussupt V., Mendez-Rivera L., Bai H., Wieczorek L., Mayer S.V., Zemil M., Wagner D.A., et al. Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques. Nat. Commun. 2024;15:200. doi: 10.1038/s41467-023-44265-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-44265-0</ArticleId><ArticleId IdType="pmc">PMC10764318</ArticleId><ArticleId IdType="pubmed">38172512</ArticleId></ArticleIdList></Reference><Reference><Citation>Navas C., Manso T., Martins F., Minto L., Moreira R., Minozzo J., Antunes B., Vale A., McDaniel J.R., Ippolito G.C., Felicori L.F. The major role of junctional diversity in the horse antibody repertoire. Mol. Immunol. 2022;151:231–241. doi: 10.1016/j.molimm.2022.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2022.09.011</ArticleId><ArticleId IdType="pubmed">36179605</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Straten K., Guerra D., van Gils M.J., Bontjer I., Caniels T.G., van Willigen H.D.G., Wynberg E., Poniman M., Burger J.A., Bouhuijs J.H., et al. Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron. Immunity. 2022;55:1725–1731.e4. doi: 10.1016/j.immuni.2022.07.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.07.018</ArticleId><ArticleId IdType="pmc">PMC9353602</ArticleId><ArticleId IdType="pubmed">35973428</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilks S.H., Mühlemann B., Shen X., Türeli S., LeGresley E.B., Netzl A., Caniza M.A., Chacaltana-Huarcaya J.N., Corman V.M., Daniell X., et al. Mapping SARS-CoV-2 antigenic relationships and serological responses. Science. 2023;382 doi: 10.1126/science.adj0070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adj0070</ArticleId><ArticleId IdType="pubmed">37797027</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopardo G., Belloso W.H., Nannini E., Colonna M., Sanguineti S., Zylberman V., Muñoz L., Dobarro M., Lebersztein G., Farina J., et al. RBD-specific polyclonal F(ab )(2) fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial. EClinicalMedicine. 2021;34 doi: 10.1016/j.eclinm.2021.100843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.100843</ArticleId><ArticleId IdType="pmc">PMC8037439</ArticleId><ArticleId IdType="pubmed">33870149</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimber C., Valk S.J., Chai K.L., Piechotta V., Iannizzi C., Monsef I., Wood E.M., Lamikanra A.A., Roberts D.J., McQuilten Z., et al. Hyperimmune immunoglobulin for people with COVID-19. Cochrane Database Syst. Rev. 2023;1 doi: 10.1002/14651858.CD015167.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD015167.pub2</ArticleId><ArticleId IdType="pmc">PMC9887673</ArticleId><ArticleId IdType="pubmed">36700518</ArticleId></ArticleIdList></Reference><Reference><Citation>Malyala P., Singh M. Endotoxin limits in formulations for preclinical research. J. Pharmacol. Sci. (Tokyo, Jpn.) 2008;97:2041–2044. doi: 10.1002/jps.21152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.21152</ArticleId><ArticleId IdType="pubmed">17847072</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O., Graham B.S., McLellan J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164637</ArticleId><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce M.G., Sankhala R.S., Chen W.H., Choe M., Bai H., Hajduczki A., Yan L., Sterling S.L., Peterson C.E., Green E.C., Smith C. A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein. BioRxiv. 2020 doi: 10.1101/2020.03.15.992883. Preprint at.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.15.992883</ArticleId></ArticleIdList></Reference><Reference><Citation>Motulsky H.J., Brown R.E. Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinformatics. 2006;7:123. doi: 10.1186/1471-2105-7-123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-7-123</ArticleId><ArticleId IdType="pmc">PMC1472692</ArticleId><ArticleId IdType="pubmed">16526949</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez E.J., Chang W.C., Chen W.H., Hajduczki A., Thomas P.V., Jensen J.L., Choe M., Sankhala R.S., Peterson C.E., Rees P.A., Kimner J. SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity. iScience. 2024</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>